The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 35 years experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of injections pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands, mylife Diabetescare directly to patients or through pharmacies and clinics, and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies.
Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors.
Brunnmattstrasse 6, 3401 Burgdorf – Switzerland
|Date||Trading entity / Person||Association||Trade type||Volume|
|23.06.22||None||Non-Executive member||Buy||CHF 31,400.00|
|23.06.22||None||Executive member||Buy||CHF 11,760.00|
|23.06.22||None||Executive member||Buy||CHF 122.50|
|14.06.22||None||Non-Executive member||Buy||CHF 1,080,875.72|
|13.06.22||None||Non-Executive member||Buy||CHF 200,296.80|
|10.06.22||None||Non-Executive member||Buy||CHF 203,240.19|
|07.06.22||None||Non-Executive member||Buy||CHF 135,037.40|
|25.05.22||None||Non-Executive member||Buy||CHF 68,736.00|
|24.03.22||None||Non-Executive member||Buy||CHF 144,874.35|
|23.03.22||None||Non-Executive member||Buy||CHF 216,056.16|
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.